A total of 356 patients with HR-positive and HER2-positive breast cancer were randomized to two cycles of conventional TCHP regimen (docetaxel, carboplatin, trastuzumab, and pertuzumab) vs. a chemotherapy-free regimen with trastuzumab and pertuzumab in combination with endocrine treatment. This evidence concerns the gene ERBB2 and breast carcinoma.